PressMarch 16, 2023 R&A PSYINS Announces Strategic Partnership with Nucleus to Provide the Psychedelic Industry Insurance Coverage
PressMarch 15, 2023 Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
PressMarch 15, 2023 Filament Health Announces FDA Approval of Phase II Clinical Trial Studying Psilocybin for Methamphetamine Use Disorder
PressMarch 15, 2023 Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
PressMarch 10, 2023 Betterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”
PressMarch 9, 2023 Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
PressMarch 8, 2023 Numinus Wellness Inc. Executives to Present on Panel at Upcoming South by Southwest Conference
PressMarch 8, 2023 Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results
PressMarch 8, 2023 Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference
PressMarch 7, 2023 Safe Supply and Origin Therapeutics Announces Engagement of Research Capital and Upsizing of Brokered Financing To $4 Million
PressMarch 6, 2023 Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
PressMarch 6, 2023 Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership
PressMarch 3, 2023 Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
PressMarch 3, 2023 GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
